DHTML Menu By Milonic JavaScript
contact ussite map
Juvaris Beotherapeutics, Inc.

Board of Directors

Thomas P. Monath, M.D. (Kleiner Perkins Caufield & Byers)

Dr. Monath was appointed to the Board of Directors in 2006 following the Series A equity investment made by KPCB. Dr. Monath is a Partner, Pandemic and Biodefense Fund, at Kleiner Perkins Caufield & Byers. He is also Adjunct Professor, Harvard School of Public Health. Between 1992 and 2006, Dr. Monath was Chief Scientific Officer and an Executive Director at Acambis, plc where he directed R&D on dengue, West Nile, Japanese encephalitis, yellow fever, Clostridium difficile, and smallpox vaccines for defense against bioterrorism. Dr. Monath retired from the US Army as a Colonel in 1992 after 24 years in the uniformed services. Between 1973 and 1988, he was Director, Division of Vector-Borne Viral Diseases, Centers for Disease Control, Fort Collins, CO and from 1989-1992 he was Chief, Virology Division, US Army Medical Research Institute of Infectious Diseases (USAMRIID). He has served on numerous government and international committees on infectious diseases, biosecurity, World Health Organization expert committees and the National Vaccines Advisory Committee (USA). Dr. Monath received his undergraduate degree from Harvard College and his M.D. from Harvard Medical School and trained in internal medicine at the Peter Bent Brigham Hospital, Boston. Dr. Monath is also Adjunct Professor, Harvard School of Public Health and on the editorial board of five scientific journals.

^ back to top

Michael Ross, Ph.D. (SV Life Sciences)

Dr. Ross was appointed to the Board of Directors in 2009. He is a Managing Partner at SV Life Sciences based in San Francisco. Prior to that, he was the tenth employee at Genentech where he worked for 13 years. He served as Genentech team leader for Humulin® (human insulin-Lilly), Roferon® (Interferon alpha-Roche), Protropin® (hGH), Vice President of Development during the development of Activase®, Nutropin® and Pulmozyme®. He then started Genentech's protein engineering and small molecule discovery effort as Vice President of Medicinal and Biomolecular Chemistry. He was the Founding CEO of Arris Pharmaceutical, (now part of Celera), MetaXen, (now part of Exelixis), ExSAR and CyThera (now part of Novocell). He was most recently Managing Partner in Didyma, LLC, a biotechnology management consulting firm. In addition to Juvaris, he serves on the boards of Adimab, Alinea, Archemix, Intranasal, Itero Biopharmaceuticals, Link Medicine, Mpex, NKT Therapeutics, Sutro Pharmaceuticals and the Thayer School of Engineering (Dartmouth College). He has also served on the boards of Aderis Pharmaceuticals, Arris Pharmaceutical, Carta Proteomics, CyThera, Glycofi, Epimmune, Genencor, MetaXen, Rinat and Xenova. Dr. Ross received his AB from Dartmouth College, his PhD in Chemistry at Caltech, and completed a Post Doctorate in Molecular Biology at Harvard.

^ back to top

Lewis T. "Rusty" Williams, M.D., Ph.D. (Five Prime Therapeutics, Inc.)

Dr. Williams was appointed to the Board of Directors as Director in 2007. Dr. Williams founded Five Prime Therapeutics, Inc. in 2002, serving as its Executive Chairman and leading its research and development efforts. Prior to founding Five Prime, Dr. Williams was President of Chiron Technologies (a business unit of Chiron Corporation) from 1994 to 1998, and Chief Scientific Officer, President of R&D and a member of the Board of Directors of Chiron Corporation from 1998 to 2001. Previous to Chiron, Dr. Williams was a Howard Hughes Medical Institute investigator at the University of California, San Francisco. Earlier in his career he was on the faculty of Harvard Medical School. Dr. Williams is a co-Founder of COR Therapeutics, Inc. and served as a member of its Board of Directors from 1988 to 1994. He is a member of the National Academy of Sciences and a fellow of the American Academy of Arts & Sciences. Dr. Williams earned his M.D. and Ph.D. degrees from Duke University.

^ back to top

Carol L. Brosgart, M.D., (Children's Hospital & Research Center Oakland)

Dr. Brosgart was appointed to the Board of Directors in 2007. Dr. Brosgart is Senior Vice President & Chief Medical Officer at Children's Hospital & Research Center Oakland. Previously, Dr. Brosgart was involved in the development of antiviral therapies at Gilead Sciences, Inc., a biotechnology company dedicated to advancing therapeutics against life-threatening diseases worldwide. Most recently, she served as Vice President, Public Health and Policy, and prior to that she served as Vice President, Medical Affairs and Vice President, Clinical Research. She led the development efforts leading to licensure of both VireadŽ (tenofovir disoproxil fumarate), for the treatment of HIV, and HepseraŽ (adefovir dipivoxil), for the treatment of chronic hepatitis B. She also focused on public health and policy, where her domestic and global efforts focused on seasonal and pandemic influenza planning; HIV testing; increasing awareness, screening and linkage to care for chronic hepatitis B and C; and improved access to care and chronic disease management of infectious diseases of public health importance. Before joining Gilead, she spent more than 20 years in public health, clinical medicine, and clinical research at the Alameda County Health Care Services Agency, Oakland, CA and at Alta Bates Medical Center in Berkeley, CA. She was one of the first physicians in the U.S. caring for patients with HIV/AIDS and was the founder and Medical Director of the East Bay AIDS Center. While in practice, she was an active member of the clinical faculty of the School of Medicine at the University of California (San Francisco and Berkeley). Dr. Brosgart earned her B.S. degree from the University of California, Berkeley and her M.D. from the University of California, San Francisco.

^ back to top

Grant E. Pickering (Juvaris BioTherapeutics, Inc.)

In the first quarter of 2008, Mr. Pickering was appointed President and CEO, and also elected to the Company's Board of Directors. Prior to joining Juvaris, Mr. Pickering founded Pharmada, Inc. with the Fred Hutchinson Cancer Research Center and served as its President and Chief Executive Officer. This biopharmaceutical company focused on the development of small-molecule therapeutics for the treatment of cancer. From 2000 through 2005, Mr. Pickering was employed by Dendreon Corporation where he served as a Corporate Officer and as its Senior Vice President of Operations. During his tenure at Dendreon, he led clinical development, manufacturing, sales, marketing, business development, project management, while playing a major role in fundraising activities, including the company's initial public offering. Before Dendreon, he held senior management roles in marketing and business development with Algos Pharmaceutical Corporation prior to participating in its sale to Endo Pharmaceuticals. Prior to Algos, Mr. Pickering was in sales- and marketing-related roles with Glaxo and Johnson & Johnson's Ortho Pharmaceutical Corporation. Mr. Pickering earned his B.S. degree in marketing from The Pennsylvania State University and was Beta Gamma Sigma at Georgetown University's MBA program graduating magna cum laude.

^ back to top

© 2014 Juvaris BioTherapeutics.